Key Points
- Amneal Pharmaceuticals EVP Nikita Shah sold 146,403 shares at an average price of $17.51, generating approximately $2.56 million and reducing her holdings by 36.62%.
- AMRX shares opened at $17.27, while analysts maintain a consensus “Buy” rating and an average price target of $17.67, suggesting limited upside from recent levels.
- The company’s higher guidance and expanded biosimilars pipeline, including the Kashiv transaction, support its growth outlook, but investors face risks from Rytary revenue erosion, execution challenges and recent insider selling.
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) EVP Jason Daly sold 6,613 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $17.70, for a total value of $117,050.10. Following the sale, the executive vice president directly owned 245,171 shares of the company's stock, valued at approximately $4,339,526.70. This represents a 2.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Amneal Pharmaceuticals Stock Performance
Shares of AMRX opened at $17.27 on Friday. The stock has a market capitalization of $5.51 billion, a P/E ratio of 35.24 and a beta of 1.27. The company has a debt-to-equity ratio of 77.65, a quick ratio of 1.44 and a current ratio of 2.20. Amneal Pharmaceuticals, Inc. has a 1 year low of $9.15 and a 1 year high of $19.26. The company's fifty day moving average is $17.15 and its two-hundred day moving average is $14.56.
Institutional Trading of Amneal Pharmaceuticals
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Intech Investment Management LLC grew its holdings in shares of Amneal Pharmaceuticals by 1.2% during the fourth quarter. Intech Investment Management LLC now owns 97,573 shares of the company's stock worth $1,229,000 after buying an additional 1,159 shares in the last quarter. Hsbc Holdings PLC lifted its holdings in shares of Amneal Pharmaceuticals by 1.6% during the 4th quarter. Hsbc Holdings PLC now owns 101,945 shares of the company's stock worth $1,297,000 after acquiring an additional 1,569 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Amneal Pharmaceuticals by 2.4% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 68,137 shares of the company's stock worth $859,000 after acquiring an additional 1,582 shares during the period. Comerica Bank boosted its position in shares of Amneal Pharmaceuticals by 56.1% in the fourth quarter. Comerica Bank now owns 4,690 shares of the company's stock worth $59,000 after acquiring an additional 1,685 shares during the last quarter. Finally, Kemnay Advisory Services Inc. purchased a new stake in Amneal Pharmaceuticals in the fourth quarter valued at approximately $26,000. Hedge funds and other institutional investors own 31.82% of the company's stock.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently commented on AMRX shares. Barclays raised their price objective on shares of Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an "overweight" rating in a research report on Wednesday, May 20th. Wall Street Zen upgraded shares of Amneal Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Sunday, July 12th. Zacks Research raised shares of Amneal Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Friday, August 7th. Weiss Ratings downgraded shares of Amneal Pharmaceuticals from a "buy (b-)" rating to a "hold (c+)" rating in a report on Wednesday. Finally, The Goldman Sachs Group reiterated a "buy" rating and issued a $21.00 price objective on shares of Amneal Pharmaceuticals in a research note on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $17.67.
Read Our Latest Analysis on AMRX
Trending Headlines about Amneal Pharmaceuticals
Here are the key news stories impacting Amneal Pharmaceuticals this week:
- Positive Sentiment: Amneal entered the second half of 2026 with higher guidance and a broader product pipeline, supporting the company’s growth outlook. However, erosion of its Rytary product remains a concern. Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist?
- Positive Sentiment: The Kashiv transaction gives Amneal an integrated biosimilars platform that could become a significant long-term growth engine, expanding its pipeline and commercial opportunities. Integration, regulatory execution and product adoption are key hurdles. Can Amneal's Kashiv Deal Turn Biosimilars Into a Major Growth Engine?
- Neutral Sentiment: Brokerages have a consensus price target of $17.67, indicating limited potential upside relative to recent trading levels and suggesting analysts see a fairly balanced risk-reward profile. Amneal Pharmaceuticals Receives $17.67 Consensus Price Target
- Neutral Sentiment: AMRX has rallied 44.8% over three months, but the advance now faces tests from upcoming earnings, new product launches and pipeline progress. Its higher valuation and Rytary revenue erosion could limit further gains. AMRX Stock Surges 44.8% in 3 Months
- Negative Sentiment: Amneal executives disclosed sizable stock sales. EVP Jason B. Daly sold 210,000 shares for approximately $3.65 million and an additional 6,613 shares, while EVP Nikita Shah sold 146,403 shares for approximately $2.56 million. The transactions substantially reduced their ownership stakes and may be weighing on investor sentiment, although insider sales do not necessarily indicate deteriorating fundamentals. Amneal Executive Stock Sale Filings
Amneal Pharmaceuticals Company Profile
(
Get Free Report)
Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.
Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
